Literature DB >> 9600071

Polyoma middle T antigen activates the Ser/Thr kinase Akt in a PI3-kinase-dependent manner.

S A Summers1, L Lipfert, M J Birnbaum.   

Abstract

Polyoma middle T antigen (PMT) was originally identified as the tumorigenic component of the polyomavirus genome. To investigate whether the serine/ threonine kinase Akt/PKB, which is the proto-oncogene transduced by the transforming AKT8 retrovirus, is activated by PMT, 3T3-L1 fibroblasts were stably transfected with wild type PMT. PMT expression accelerated glucose transport and increased phosphorylation of p70 S6-kinase and MAPK. PMT expression also stimulated Akt kinase activity 7 fold as compared to untreated, mock infected cells. This stimulation rivaled that obtained following insulin treatment of both mock and PMT infected cells. Akt activation and phosphorylation were eliminated in a PMT mutant incapable of interacting with PI3-kinase, but not one which does not interact with Shc, and correlated closely to the amount of PI3-kinase activity in anti-phosphotyrosine immunoprecipitates. These results indicate that the PI3-kinase pathway is requisite, but the Shc pathway is dispensable, for Akt activation. The studies further suggest that Akt may participate in PMT and PI3-kinase's regulation of cellular transformation and tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600071     DOI: 10.1006/bbrc.1998.8575

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

Review 1.  Natural biology of polyomavirus middle T antigen.

Authors:  K A Gottlieb; L P Villarreal
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

2.  Role for Akt3/protein kinase Bgamma in attainment of normal brain size.

Authors:  Rachael M Easton; Han Cho; Kristin Roovers; Diana W Shineman; Moshe Mizrahi; Mark S Forman; Virginia M-Y Lee; Matthias Szabolcs; Ron de Jong; Tilman Oltersdorf; Thomas Ludwig; Argiris Efstratiadis; Morris J Birnbaum
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 3.  Lessons in signaling and tumorigenesis from polyomavirus middle T antigen.

Authors:  Michele M Fluck; Brian S Schaffhausen
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

4.  Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt.

Authors:  T Kitamura; Y Kitamura; S Kuroda; Y Hino; M Ando; K Kotani; H Konishi; H Matsuzaki; U Kikkawa; W Ogawa; M Kasuga
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

5.  A Transformation-Defective Polyomavirus Middle T Antigen with a Novel Defect in PI3 Kinase Signaling.

Authors:  Deborah Denis; Cecile Rouleau; Brian S Schaffhausen
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

Review 6.  Modeling gliomagenesis with somatic cell gene transfer using retroviral vectors.

Authors:  L Uhrbom; E C Holland
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

7.  Herpes simplex virus requires VP11/12 to activate Src family kinase-phosphoinositide 3-kinase-Akt signaling.

Authors:  Melany J Wagner; James R Smiley
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

8.  Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo.

Authors:  E C Holland; Y Li; J Celestino; C Dai; L Schaefer; R A Sawaya; G N Fuller
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

9.  Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide.

Authors:  S A Summers; L A Garza; H Zhou; M J Birnbaum
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

10.  Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis.

Authors:  Eric Ackah; Jun Yu; Stefan Zoellner; Yasuko Iwakiri; Carsten Skurk; Rei Shibata; Noriyuki Ouchi; Rachael M Easton; Gennaro Galasso; Morris J Birnbaum; Kenneth Walsh; William C Sessa
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.